This work not only advances understanding of microenvironment-mediated resistance but also lays the foundation for designing innovative therapeutic agents targeting the TUBA1B-microenvironment axis, ultimately improving cancer treatment outcomes. The gene discussed is TUBA1B; the disease is cancer.